Because TRAIL and TRAIL receptors (TRAILRs) have been largely characterized and shown to be involved in the extrinsic death pathway53, 54, recombinant TRAIL and agonistic antibodies against TRAILRs capable of promoting TRAIL-mediated apoptosis in tumor cells have been evaluated for their clinical potential in cancer therapy55, 56. Here, TNFSF10 is linked to neoplasm.